What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 6 minute read Pharma Industry News Kelun-Biotech reports strong Phase 3 data for sacituzumab tirumotecan in HR+/HER2- breast cancer Kelun-Biotech’s sacituzumab tirumotecan doubled PFS in HR+/HER2- breast cancer. Find out what this means for patients, investors, and China’s ADC landscape. bySrinathOctober 19, 2025